Vishwas Seshadri Sells 25,000 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) CEO Vishwas Seshadri sold 25,000 shares of the stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $4.78, for a total transaction of $119,500.00. Following the completion of the transaction, the chief executive officer now owns 1,355,322 shares of the company’s stock, valued at approximately $6,478,439.16. The trade was a 1.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Abeona Therapeutics Stock Performance

NASDAQ ABEO opened at $4.45 on Wednesday. Abeona Therapeutics Inc has a twelve month low of $3.05 and a twelve month high of $8.45. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The firm has a market cap of $215.98 million, a price-to-earnings ratio of -1.65 and a beta of 1.79. The business has a 50-day moving average price of $5.39 and a 200-day moving average price of $5.80.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.19. As a group, equities research analysts predict that Abeona Therapeutics Inc will post -1.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Abeona Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Twinbeech Capital LP purchased a new position in Abeona Therapeutics in the fourth quarter worth about $58,000. Squarepoint Ops LLC purchased a new position in Abeona Therapeutics during the 4th quarter valued at $67,000. Jane Street Group LLC bought a new position in shares of Abeona Therapeutics in the third quarter worth about $84,000. Oxford Asset Management LLP bought a new position in Abeona Therapeutics in the 4th quarter worth about $118,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Abeona Therapeutics in the third quarter worth approximately $151,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a report on Monday, March 24th. Oppenheimer began coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 target price on the stock. Finally, StockNews.com upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 24th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Abeona Therapeutics has an average rating of “Moderate Buy” and an average target price of $17.50.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.